New guidelines for pregnancy care in multiple sclerosis, drawn up by a panel of UK experts, have been published this week.
They aim to reduce uncertainty about treatments that are safe and appropriate for pregnant and breastfeeding women with MS, and for couples affected by MS who are planning a pregnancy.
MS is usually diagnosed among 20-40 year olds, two thirds of whom are women. Around this age, both men and women might be planning to have children. At the same time, it is becoming increasingly clear that disease modifying drugs (DMDs) should be started as early as possible. Delaying DMD treatment until after having a family can lead to irreversible disability in the long term. For this reason, it makes sense to start discussing family planning and pregnancy early after diagnosis, alongside discussions about DMDs, if appropriate.
However, there is limited evidence available to guide these discussions, and so the MS Trust and a group of very experienced health professionals set out to develop a set of consensus guidelines to bring clarity to this area. The guidelines have been endorsed by the Association of British Neurologists, and have been reviewed by a panel of MS specialist nurses, neurologists, obstetricians, midwives and people with MS as part of the development process.
The guidelines bring together evidence from drug specific pregnancy registers as well as published peer reviewed research. They cover pre-pregnancy counselling and DMDs for men and women, MS management during pregnancy, delivery and anaesthetic options. The guidelines also give advice for the period after birth, for breastfeeding and for the use of DMDs after the birth.
We hope that the publication of these guidelines will enable health professionals to provide more informed guidance, support and care to people with MS when they are planning a family as well as during pregnancy and the post-natal period.
- Megan Roberts, Health Professionals Programme Manager, MS Trust
- Practical Neurology 2019;19:106-114. Full article UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines
Pregnancy and MS
For most women, MS does not make any significant difference to their pregnancy. Find out how to manage MS throughout your pregnancy.
DMT use in fathers to be
3 June 2014
A study examining the outcomes of pregnancies fathered by a man with multiple sclerosis taking a disease modifying drug.
Disease modifying drugs (DMDs)
DMDs are a group of treatments for people with relapsing MS which reduce the number and severity of any relapses you might experience.
Ponesimod (Ponvory) for relapsing remitting multiple sclerosis rejected by NICE
13 Oct 2021 - 00:00
The MS Trust is very disappointed that NICE does not recommend ponesimod (Ponvory) as an NHS treatment in England and Wales.
Multiple sclerosis and disease modifying drugs, what are my options?
28 Sep 2021 - 00:00
We interview Dr Sharmilee Gnanapavan, a Consultant Neurologist at Bart's Health to get some answers on what's new in the world of disease modifying drugs and multiple sclerosis.
New report highlights barriers to accessing Sativex across the UK
18 Aug 2021 - 00:00
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.